A new study published today in Nature Communications shows a promising alternative for those who have to take a daily pill regimen. Targeting HIV treatment and prevention, researchers across multiple departments at the University of North Carolina at Chapel Hill collaborated on a seven-year study in animals to make a better injectable drug implant that can combine multiple drugs and is ultra-long-acting, while also addressing many of the challenges faced with current HIV treatment and prevention methods.
“There is no FDA-approved or marketed technology for long-acting prevention of HIV, and we are the first to use this delivery method with multiple antiretroviral drugs,” said Rahima Benhabbour, PhD, MSc, first author of the study and assistant professor in the UNC_NCSU Joint Department of Biomedical Engineering. “To have an HIV prevention treatment that consists of an injection once or twice a year would make an incredible impact for patients.” She added, “This technology is not only promising for HIV, but for any kind of condition that requires a daily intake of medication. We’re talking about a safe, removable, long-lasting injection that takes away the burden of adhering to a daily medication regimen.”
Antiretroviral drugs are used in both prevention and treatment of HIV, and multiple types are used in combination to counteract resistance to any one antiretroviral drug. These drugs need to be taken consistently every day. There are many obstacles that stand in the way of adherence to these medication regimens. Benhabbour says this especially applies to otherwise healthy people trying to prevent infection.
“In sub-Saharan Africa where prevalence of HIV is highest, accessibility to these medications can be difficult, and there is much stigma associated with the virus,” Benhabbour said. “It is a very big deal for someone who doesn’t have HIV to go out of their way to not only access the drugs, but then associate themselves with HIV by taking a pill every day.”
There’s also the factor of human error. Anyone who strives to take a daily multivitamin can understand that some days the pill gets skipped, or gets taken at a different time of day. But such small deviations can make antiretroviral drugs less effective.
“Because one of the biggest difficulties associated with HIV prevention is lack of adherence to drug treatment, we wanted to create a drug delivery system that essentially solved this problem,” said senior author J. Victor Garcia, PhD, professor of medicine at UNC School of Medicine, director of the International Center for the Advancement of Translational Science and member of the UNC Center for AIDS Research.
The injectable implant is comprised of three elements – an organic solvent, a polymer, and the drug or drugs that need to be delivered. The formulation results in a honey-like liquid that turns into a solid when injected under the skin. This phase inversion happens when the solvent diffuses into the body leaving behind the polymer and medication(s) – the combination of which determines over what time period the medication(s) will be released into the blood system.
In this study six antiretroviral drugs were tested, and all kept their physical and chemical properties within the formulation and upon release. All six were also released from the implant at effective levels for a sustained amount of time ranging from one month to a year.
The injectable drug implant created by UNC’s research team is the first to address several drawbacks to the current method of long-acting drug delivery for HIV – namely the ability to remove it and quickly eliminate the presence of residual drug(s) in the system.
“If a patient needs to withdraw from the treatment because they’ve had a bad reaction to the drug(s), or maybe a woman has become pregnant, our implant can be easily surgically removed,” said Martina Kovarova, PhD, contributing author to the study and associate professor of medicine at UNC SOM.
This is the first ever injectable implant for HIV that can be removed as early as one week, or as late as months after the injection, and have drug levels virtually eliminated from the system within one week. If the implant does not need to be removed, it biodegrades into lactic and glycolic acids, which are already found in the body and are easily absorbed.
Researchers plan to continue developing and improving this multi-drug delivery system, observing its effects in relevant in vivo models and eventually humans.
The Latest on: Injectable multi-drug delivery system
via Google News
The Latest on: Injectable multi-drug delivery system
- Covid-19 vaccine might work best as a nasal spray instead of an injectionon June 23, 2020 at 8:40 am
Researchers behind Britain's most promising Covid-19 jabs believe getting the vaccine directly into the lungs might be the best way to protect against the respiratory infection.
- Hybrid Drug Delivery Systems Made by Combining FFF 3D Printing & Conventional Manufacturingon June 23, 2020 at 7:46 am
Over the last few years, research has shown that 3D printing has a lot of potential for fabricating drug delivery systems ... of drug capsules and an injection head for filling them with drugs ...
- Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030on June 18, 2020 at 1:22 am
Reportlinker.com announces the release of the report "Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030" -.
- Electronic Drug Delivery Systems Market Worth $14.51 Billion, Globally, by 2027 at 8.5% CAGR: Verified Market Researchon June 11, 2020 at 5:29 pm
Verified Market Research recently published a report, "Electronic Drug Delivery Systems Market by Product (Electronic Autoinjectors, Electronic Injection Pens, Electronic Inhalers, Electronic Wearable ...
- Injectable Drug Delivery Market 2020 High Demands, Growth Strategies, Geographical Analysis and Forecast Till 2027on June 11, 2020 at 3:25 pm
According to an analysis by a Market Research, the global injectable drug delivery market is predicted to grow at a CAGR of 8.67% during the forecasting period 2019-2027. The incr ...
- Combo therapy, nanoparticle delivery system show promise for pancreatic canceron June 8, 2020 at 8:02 am
A new multi-drug combination therapy for pancreatic cancer is inching toward clinical trials in humans. The drug compound, called SapC-DOPS, combines chemotherapy with targeted therapy and can kill ...
- COVID-19 Impact on Injectable Drug Delivery Marketon June 8, 2020 at 3:09 am
You will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports will now feature detailed analysis that will help you make critical decisions. The Global Injectable ...
- Needle-Free Drug Injection Systems Market Report 2020 | Comprehensive Insights and Projections 2013-2027on May 29, 2020 at 4:35 pm
DUBLIN, May 29, 2020 /PRNewswire/ -- The "Needle-Free Drug Injection Systems - Global Market Trajectory ... of 9.1%. Insulin Delivery, one of the segments analyzed and sized in this study ...
- Electronic Drug Delivery Systems Market Size Worth $15.4 Billion by 2027: Grand View Research, Inc.on May 26, 2020 at 1:08 am
Read 138 page research report with ToC on "Electronic Drug Delivery Systems Market Size, Share & Trends Analysis Report by Product Type (Auto Injectors, Injection Pens), By Application (Diabetes ...
- Light drives injectionon May 18, 2020 at 8:14 am
A Max Planck research team has now succeeded in controlling the injection system optogenetically, i.e. with light (Nature Communications, "LITESEC-T3SS - Light-controlled protein delivery into ...
via Bing News